# Joyo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/joyo

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Total disclosed funding: $78M
- Latest round: Series B (Jan 6, 2022)
- Investors on record: 10

## About

Based in Guangzhou, China and established in 2017, Joyo is a pharmaceutical technology company that focuses on the research and development of tumor and autoimmune, metabolic and infectious disease drugs. The company has R&D center in Guangzhou, Shanghai, and Hangzhou. The company's R&D team has participated in First in Class (FIC), and Best in Class (BIC) drug R&D projects. In June 2023, the company closed a round of pre-series C funding.

The company engages in the research and development of tumor and autoimmune, metabolic and infectious disease drugs. The company developed PreClinical Candidate (PCC) drugs into Proof-of-Concept (PoC) drugs. It also has multiple innovative drug projects, including First in Class (FIC) and First in Disease (FID).

The company will use the pre-series C funding to advance multiple mid- to late-stage clinical programs in the company's innovative drug pipeline, including clinical phase III for innovative drugs in infectious diseases and clinical phase II programs in multiple disease areas, including oncology and autoimmunity.

## Funding rounds

- Series B, Jan 6, 2022, $31M — Hong Shan, SDIC Venture Capital, LC Ventures, Guanzi Private Equity Management (Hangzhou)
- Series B, Jul 28, 2021, $46M — Hong Shan, SDIC Venture Capital, Shanghai Xiangrong Capital, LC Ventures
- Series A, Jan 18, 2021 — Shanghai Lianhe Investment, RIASSET Investment Management, Wuxi AppTec Group
- Angel, May 28, 2018 — Yuexiu Industrial Investment Funds Management, Cisen Pharmaceutical Co., Ltd.

## Investors

- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Angel
- Cisen Pharmaceutical Co., Ltd. — Angel
- Shanghai Lianhe Investment — Series A
- RIASSET Investment Management (https://capitalatlas.ai/funds/riasset-investment-management) — Series A
- Wuxi AppTec Group — Series A
- Hong Shan — Series B
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B
- Shanghai Xiangrong Capital (https://capitalatlas.ai/funds/shanghai-xiangrong-capital) — Series B
- LC Ventures (https://capitalatlas.ai/funds/lc-ventures) — Series B
- Guanzi Private Equity Management (Hangzhou) — Series B